ASTRANA HEALTH INC

Company Overview

Astrana Health is a provider-centric, technology-enabled, risk-bearing healthcare company operating three segments: Care Partners (network and risk arrangements), Care Delivery (clinics and ancillary services) and Care Enablement (proprietary PHM/risk-scoring and MSO services). The company manages value‑based care for over a million patients (expanded to ~1.6M following the Prospect acquisition) through ~20,000 providers and generates revenue primarily from capitation, risk‑pool settlements, management fees and fee‑for‑service billing. Its footprint spans multiple states (CA, NV, TX, MD, CT, GA, HI) but revenue remains concentrated with a few large payers (~66% in 2024), and recent growth has been M&A‑driven and financed with significant debt and a multi‑facility credit package.

Executive Compensation Practices

Compensation is likely structured to reward growth in managed lives, capitation revenue, successful integration of acquisitions (e.g., Prospect), and improvements in risk‑adjusted outcomes and cost management (Adjusted EBITDA, medical-loss ratios, and cash flow conversion). The MD&A highlights rising stock‑based compensation and transaction/integration costs, so long‑term equity (RSUs/options), transaction/retention awards and contingent earnouts are likely prominent to align executives and physician leaders with multi‑year value creation. Given higher leverage, interest expense and timing volatility of risk‑pool settlements, compensation plans may place greater weight on liquidity, free cash flow and downside protections (clawbacks or performance gates tied to regulatory/compliance milestones) than pure revenue growth alone.

Insider Trading Considerations

Material nonpublic events that could move the stock include enrollment and capitation shifts, the timing and size of risk‑pool settlements (which settle with long lags), acquisition closings/integration milestones (Prospect and other deals), and debt draws/credit package actions; insiders will likely trade around these catalysts but are subject to standard blackout windows and pre‑clearance requirements. Watch for increased insider sales after large equity grants (stock‑based comp) or after major M&A closings when executives may monetize equity for diversification; conversely, insiders may hold through integration if retention awards vest on performance. Regulatory exposure (Anti‑Kickback/Stark, False Claims, Knox‑Keene licensure, HIPAA) raises the compliance risk of trading on material information, making 10b5‑1 plans, Form 4 filings and disclosure timing particularly important to monitor.